Hydralazine therapy in hypertensive patients with idiopathic systemic lupus erythematosus
Open Access
- 1 July 1975
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 18 (4), 335-338
- https://doi.org/10.1002/art.1780180407
Abstract
Seven hypertensive patients with idiopathic systemic lupus erythematosus were treated with hydralazine. They received a mean daily dose of 203 mg for a mean duration of 21 months. All were taking prednisone alone or in combination with azathioprine. During therapy with hydralazine, there were no new symptoms nor exacerbation of pre-existing symptoms attributable to systemic lupus. Laboratory parameters, including antinuclear antibody titers and complement levels, either improved or remained stable. The results indicate that hydralazine can be safely used in hypertensive patients with systemic lupus who are receiving concomitant immunosuppressive therapy.Keywords
This publication has 6 references indexed in Scilit:
- Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritisAmerican Journal Of Medicine, 1973
- Immune Responses to Hydralazine and Nuclear Antigens in Hydralazine-Induced Lupus ErythematosusAnnals of Internal Medicine, 1972
- Essential CryoglobulinemiaArchives of Internal Medicine, 1970
- CLINICAL AND EXPERIMENTAL STUDIES ON THE HYDRALAZINE SYNDROME AND ITS RELATIONSHIP TO SYSTEMIC LUPUS ERYTHEMATOSUSMedicine, 1967
- Antinuclear Factors in Systemic Lupus Erythematosus and Rheumatoid ArthritisAnnals of Internal Medicine, 1965
- Lupus Diathesis and the Hydralazine SyndromeNew England Journal of Medicine, 1965